Evrofarma SA

AT:EVROF Greece Packaged Foods
Market Cap
$48.28 Million
€47.04 Million EUR
Market Cap Rank
#27335 Global
#63 in Greece
Share Price
€3.44
Change (1 day)
+0.88%
52-Week Range
€1.65 - €4.00
All Time High
€4.00
About

Evrofarma SA produces and sells dairy products in Greece. It offers milk, yoghurt, and cheese products, as well as fermented beverages. The company also exports its products. Evrofarma SA was founded in 1991 and is headquartered in Didymoteicho, Greece.

Evrofarma SA (EVROF) - Net Assets

Latest net assets as of December 2022: €14.03 Million EUR

Based on the latest financial reports, Evrofarma SA (EVROF) has net assets worth €14.03 Million EUR as of December 2022.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€48.81 Million) and total liabilities (€34.79 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets €14.03 Million
% of Total Assets 28.74%
Annual Growth Rate 5.32%
5-Year Change 20.35%
10-Year Change N/A
Growth Volatility 4.16

Evrofarma SA - Net Assets Trend (2014–2022)

This chart illustrates how Evrofarma SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Evrofarma SA (2014–2022)

The table below shows the annual net assets of Evrofarma SA from 2014 to 2022.

Year Net Assets Change
2022-12-31 €14.03 Million +11.28%
2021-12-31 €12.61 Million -2.67%
2020-12-31 €12.95 Million +9.10%
2019-12-31 €11.87 Million +1.85%
2018-12-31 €11.65 Million +8.64%
2017-12-31 €10.73 Million +5.17%
2016-12-31 €10.20 Million +4.17%
2015-12-31 €9.79 Million +5.69%
2014-12-31 €9.27 Million --

Equity Component Analysis

This analysis shows how different components contribute to Evrofarma SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 458900000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2022)

Component Amount Percentage
Retained Earnings €960.00K 6.84%
Common Stock €12.03 Million 85.78%
Other Components €1.03 Million 7.38%
Total Equity €14.03 Million 100.00%

Evrofarma SA Competitors by Market Cap

The table below lists competitors of Evrofarma SA ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Evrofarma SA's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2021 to 2022, total equity changed from 12,605,000 to 14,027,000, a change of 1,422,000 (11.3%).
  • Net income of 1,419,000 contributed positively to equity growth.

Equity Change Factors (2021 to 2022)

Factor Impact Contribution
Net Income €1.42 Million +10.12%
Other Changes €3.00K +0.02%
Total Change €- 11.28%

Book Value vs Market Value Analysis

This analysis compares Evrofarma SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.35x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 3.63x to 3.35x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2020-12-31 €0.95 €3.44 x
2021-12-31 €0.92 €3.44 x
2022-12-31 €1.03 €3.44 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Evrofarma SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 10.12%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 3.13%
  • • Asset Turnover: 0.93x
  • • Equity Multiplier: 3.48x
  • Recent ROE (10.12%) is above the historical average (4.08%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2014 -3.02% -1.11% 0.53x 5.10x €-1.21 Million
2015 5.38% 1.78% 0.67x 4.53x €-452.30K
2016 4.04% 1.43% 0.66x 4.29x €-608.10K
2017 5.00% 1.75% 0.68x 4.20x €-536.80K
2018 8.40% 3.01% 0.74x 3.80x €-186.50K
2019 1.32% 0.47% 0.81x 3.47x €-1.03 Million
2020 8.34% 3.18% 0.73x 3.58x €-215.10K
2021 -2.82% -0.97% 0.79x 3.69x €-1.62 Million
2022 10.12% 3.13% 0.93x 3.48x €16.30K

Industry Comparison

This section compares Evrofarma SA's net assets metrics with peer companies in the Packaged Foods industry.

Industry Context

  • Industry: Packaged Foods
  • Average net assets among peers: $151,124,966
  • Average return on equity (ROE) among peers: 0.84%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Evrofarma SA (EVROF) €14.03 Million -3.02% 2.48x $13.16 Million
Flour Mills Kepenos S.A. (KEPEN) $18.87 Million 1.65% 1.09x $1.41 Million
Kri-Kri Milk Industry S.A (KRI) $127.45 Million 27.11% 0.40x $239.54 Million
Loulis Mills S.A. (KYLO) $97.55 Million 1.89% 1.28x $31.66 Million
Flour Mills C. Sarantopoulos S.A. (KYSA) $3.35 Million -4.18% 6.04x $2.99 Million
Marfin Investment Group Holdings S.A (MIG) $508.40 Million -22.26% 4.55x $12.63 Million